Senest opdateret: 16. nov. 2026, 00.00

Bavarian Nordic Exchange (CO, DKK)

BAVA.CO

241.60
-5.20 (-2.11%)
HealthcareBiotechnology
Invester i dag
Invester i dag
1 års afkast (CAGR)
2.37%
3 års afkast (CAGR)
21.64%
5 års afkast (CAGR)
-4.74%
10 års afkast (CAGR)
5.36%
Aktieanalyse

Adobe 2026 Q3 – Er det stemningen, der driver prisen?

Læs mere
Markedsværdi
18.02B
Pris/omsætning
2.86
Ent værdi
18.75B
Pris/bog
1.36
Udbytte afkast
0.00%
Vekst år
-
Udbyttevækst
-
FCF-udbetaling
0.00%
Efterfølgende P/E
11.68
PEG
-
Fremtidig P/E
21.48
EPS-vekst
27.98%

Oplysninger om aktier

iO Charts Blog

Hvad er en børs? Drift, aktører, eksempler

Læs mere

Aktiediagram

Loading...
Aktiekurs-data
Åbning247.00
Daglig høj247.00
Daglig lav241.60
Daglig volumen115K
Højeste gennem alle tider401.70
1 års analytiker estimat280.00
Beta1.02
EPS (TTM)20.31
Udbytte pr. aktie0.00
Ex-div dato-
Næste dato for resultatpræsentation12 Mar 2026

Klar til at udnytte vækstpotentialet i Bavarian Nordic?

Tag det næste skridt i din portefølje.

Invester i dag

Nedsidepotensial

Loading...
Nedsidepotensial-data
BAVA.COS&P500
Nuværende prisfald fra top notering-40.40%-5.02%
Højeste prisfald-91.83%-56.47%
Højeste efterår dato30 Sep 20029 Mar 2009
Gennemsnitlig fald fra toppen-48.24%-10.64%
Gennemsnitlig tid til nyt højdepunkt101 days12 days
Maks. tid til nyt højdepunkt1935 days1805 days
Nyheder
Bavarian Nordic (CPSE:BAVA) moved into focus after its third quarter 2026 report, which paired higher earnings per share with a lower quarterly net income figure compared with the prior year. The Bava...
14. november 2026
Bavarian Nordic has delivered a strong multi‑year share price run, which puts a spotlight on whether the cash the business can generate really supports where the stock trades today. With fresh contrac...
13. november 2026
Bavarian Nordic (CPSE:BAVA) has secured a multi-year contract with the UK government to supply its MVA-BN vaccine. The agreement extends the firm's role as a supplier to a major national health author...
13. november 2026
Investing.com -- Bavarian Nordic A/S reported third-quarter revenue that exceeded analyst expectations, driven by strong growth in its travel health vaccine portfolio.
13. november 2026
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the share buy-back program announced on August 21, under which the Company intends to repu...
13. november 2026
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the third quarter and first nine months of 2026. Financ...
13. november 2026
COPENHAGEN, Denmark, November 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that Henrik Juuel has informed the Board of Directors of his decision to step down as Chief Financial Officer. ...
13. november 2026
Bavarian Nordic has secured a four-year contract from the UK Government to supply its MVA-BN vaccine, used for the prevention of mpox and smallpox.
3. november 2026
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on September 1, 2026, has now been completed, reach...
2. november 2026
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency (U...
2. november 2026